

## **ImmuteP to Participate in November Investor Events**

**SYDNEY, AUSTRALIA – 02 November 2023** – [ImmuteP Limited](#) (ASX: IMM; NASDAQ: IMMP) ("ImmuteP" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will participate in the following upcoming investor events in November:

### **Baird's Biotech Discovery Series**

Details: Marc Voigt (CEO), Dr. Frederic Triebel (CSO), Christian Mueller (SVP, Regulatory & Strategy), and Dr. Wade Iams, Assistant Professor of Medicine, Director of Thoracic Clinical Trials at Vanderbilt University Medical Center, will participate in a fireside chat.

Date: Thursday, 9 November 2023

Time: 10:30AM ET

### **Jefferies London Healthcare Conference**

Details: Marc Voigt (CEO) will present a corporate overview and update.

Date: Wednesday, 15 November 2023

Time: 3:00PM GMT (11:00AM ET)

Live webcasts and replays of the fireside chat and Mr. Voigt's presentation at the Jefferies conference will be available under the Investors & Media section of ImmuteP's website.

### **About ImmuteP**

ImmuteP is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. ImmuteP is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit [www.immuteP.com](http://www.immuteP.com).

### **Australian Investors/Media:**

Catherine Strong, Citadel-MAGNUS

+61 (0)406 759 268; [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)

### **U.S. Media:**

Chris Basta, VP, Investor Relations and Corporate Communications

+1 (631) 318 4000; [chris.basta@immuneP.com](mailto:chris.basta@immuneP.com)

This announcement was authorised for release by the CEO of ImmuteP Limited.